Gilead Sciences, Inc. (SNSE:GILD)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 182.82T +37.0% |
| Revenue (ttm) | 28.06T +5.5% |
| Net Income | -2.99T |
| EPS | -2,409.19 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 17.73 |
| Dividend | 3,039.29 (2.08%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 150.56 |
| Day's Range | n/a |
| 52-Week Range | 110.29 - 150.56 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Genetic discovery yields clues toward reversal of Alzheimer's brain damage
Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We also report on an experimental Gilead therapy showing great promise against a...
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP...
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organizati...
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to incl...
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
U.S. drugmaker Gilead Sciences said on Tuesday it had reached an agreement with the Pan American Health Organization to widen access to its HIV prevention drug across Latin America and the Caribbean...
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacap...
Gilead Sciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The event highlighted a robust, diversified portfolio with major advances in HIV prevention and treatment, including strong Yeztugo uptake and new long-acting options. Oncology and immunology pipelines are advancing, with anito-cel poised for launch and new I&I data expected soon.
Gilead Sciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Strong HIV franchise growth is driven by Sunlenca and BIKTARVY, with new launches and pipeline advances in HIV, cell therapy, and I&I. Strategic acquisitions and disciplined capital allocation support a robust, diversified portfolio, with manageable policy impacts expected.
Gilead Sciences Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing a diversified pipeline across virology, oncology, and inflammation, with multiple new launches and promising clinical data expected in the next year. Key assets include long-acting HIV regimens, novel cell therapies, ADCs, and innovative inflammation treatments.
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines.
US FDA approves Gilead's once-daily combination pill for HIV treatment
The U.S. Food and Drug Administration has approved Gilead Sciences' once daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the co...
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment...
U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), th...
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Health...
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hz...
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to ...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europ...
AHF Crowns Gilead Corporate Welfare King
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
Gilead Sciences Earnings Call Transcript: Q2 2026
Base business sales grew 10% year-over-year, led by HIV, oncology, and liver disease, with PrEP sales doubling and Trodelvy up 26%. Full-year guidance was raised for both sales and EPS, reflecting strong execution and new product launches. Recent acquisitions and FDA approvals further strengthen the pipeline.
Gilead Sciences Earnings release: Q2 2026
Gilead Sciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Gilead Sciences Slides: Q2 2026
Gilead Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Gilead Sciences Quarterly report: Q2 2026
Gilead Sciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
Gilead second-quarter sales rise 8%, beating Wall Street estimates
Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs related to a series of acquisitions...